04:32 PM EDT, 04/16/2024 (MT Newswires) -- Neurocrine Biosciences ( NBIX ) is extending its research partnership with Sentia Medical Sciences to develop and commercialize medicines to treat a variety of hypothalamic-pituitary-adrenal axis modulated diseases, Sentia said Tuesday.

Sentia and Neurocrine will continue their work to identify unique peptide antagonists targeting corticotropin-releasing factors and advancing them to development stage.

Once the candidates reach development, Neurocrine will have sole responsibility for further development, production, regulatory and commercial activities, while Sentia will be eligible for milestone and royalty payments for any products created through the collaboration.

Financial terms of the collaboration were not disclosed.